Background: There are limited data regarding the incidence and long-term impact of acute kidney injury (AKI) according to the KDIGO guidelines on the outcome in patients with myocardial infarction (MI) treated with percutaneous coronary intervention (PCI). The aim of the study was to evaluate the prevalence of AKI, as classified by the KDIGO criteria, and its association with long-term mortality. Methods: Data from 5,859 MI patients undergoing PCI at our institution were analyzed. We compared the group without and with AKI according to the KDIGO criteria in relation to long-term mortality. Results: AKI was documented in 499 (8.5%) patients. AKI stage 1 occurred in 6.2% of patients, AKI stage 2 in 0.9% of patients, and AKI stage 3 in 1.5% of patients. Patients with AKI had a higher long-term mortality (57.3 vs. 20.6%; p < 0.0001). The mortality was 50.3% in AKI stage 1, 56.9% in AKI stage 2, and 87.2% in AKI stage 3. The hazard ratios for all-cause mortality for AKI stages 1-3 were 1.77, 1.85, and 6.30 compared to patients with no AKI. Cardiogenic shock, bleeding, heart failure, age, renal dysfunction, diabetes, hyperlipidemia, ST-elevation MI, contrast volume/glomerular filtration ratio, P2Y12 receptor antagonists, and radial access were associated with the development of AKI. Conclusion: A slight increase in serum creatinine was associated with a progressive increase in long-term mortality in patients with AKI according to the KDIGO definition.
Introduction
Patients undergoing invasive treatment of myocardial infarction (MI) are at high risk of acute kidney injury (AKI) [1, 2] . In this group, AKI is associated with contrast volume, hemodynamic impairment, inflammation, bleeding, and nephrotoxic agents [1, 3, 4] . However, the incidence of AKI reported varies considerably with the population evaluated and the definitions used [1, 6] . There are limited data regarding the incidence and long-term impact on the outcome of AKI according to the KDIGO guidelines in patients with MI treated with percutaneous coronary intervention (PCI) [5] . The "Kidney Disease: Improving Global Outcomes (KDIGO)" expanded the time frame for AKI detection from the previous 48-72 h to within 7 days [7] . We aimed to evaluate the prevalence of AKI, as classified by the KDIGO criteria, in MI patients treated with PCI, and its association with long-term all-cause mortality.
Methods
A retrospective, single-center observational study was performed at the University Medical Center Maribor, a tertiary referral hospital with a 24/7 primary PCI service. We reviewed 6,387 consecutive MI patients who were treated with PCI between January 2007 and December 2016. The definition of MI was based on current guidelines [8] [9] [10] . We excluded patients on dialysis (97 [1.5%]), patients without data on serum creatinine before or after PCI (149 [2.3%]), and/or patients who died in less than 7 days after admission (282 [4.4%]), since it was assumed that such patients would have had a fair chance of developing AKI within 7 days if they had survived, leaving 5,859 (91.7%) for further analysis. No thrombolysis was used.
Patients were treated according to the guidelines for the management of MI [8, 9] . The PCI strategy and concomitant medication were at the discretion of the operator.
Renal protection with continuous infusion of saline (1 mL/kg/h during PCI and the next 12 h) was given. In patients with overt heart failure, the hydration rate was reduced at the discretion of the operator and/or attending physician. Patients who received P2Y12 receptor inhibitors prior to or during hospitalization before, during, or after PCI, and were discharged with these drugs, were recognized as having received these drugs.
All-cause mortality was assessed over a mean period of 4.2 ± 3.0 years up to January 1, 2018. All medical records were obtained from the hospital information system to complete the data collection.
The initial serum creatinine at admission was used to determine the baseline renal function. Renal dysfunction was defined as an estimated glomerular filtration rate (eGFR) less than 60 mL/kg/1.73 m 2 . The Modification of Diet in Renal Disease Study formula was used for calculations of eGFR [11] . Serum creatinine levels were determined on admission and after 24 and 48 h. After the first 48 h, serum creatinine levels were obtained at various time points, at the discretion of the treating physician.
AKI was determined using the KDIGO criteria, as follows [7] : stage 1 -a rise in serum creatinine by ≥0.3 mg/dL within 48 h, or an increase in serum creatinine of at least 1.5 times the baseline that is known or presumed to have occurred within the prior 7 days; stage 2 -more than a 2-to 2.9-fold increase in serum creatinine; stage 3 -more than a 3-fold increase in serum creatinine from the baseline or an increase in serum creatinine to > 4.0 mg/dL.
The nonionic contrast agent iopamidol (concentration 370 mgI/mL -Iopamiro 370R, Bracco) was used in our laboratory. Information on the contrast volume used during PCI was available for 5,412 (90.7%) patients.
Anemia was defined as proposed by the World Health Organization: a serum hemoglobin level < 130 g/L for men and < 120 g/L for women [12] . The Bleeding Academic Research Consortium (BARC) bleeding criteria and BARC 3a bleeding (Hb drop of 30-50 g/L or any transfusion) were used [13] . Thrombolysis in Myocardial Infarction (TIMI) flow grades were used for coronary flow assessment [14] .
Cardiogenic shock on admission was defined according to clinical and hemodynamic criteria, including hypotension (systolic blood pressure ≤90 mm Hg for ≥30 min or the need for supportive measures to maintain a systolic blood pressure of > 90 mm Hg) and evidence of end-organ hypoperfusion.
Heart failure (excluding cardiogenic shock) was defined according to the clinical criteria (bilateral pulmonary rales, S 3 gallop, edema) and/or ejection fraction < 30% and/or pulmonary edema on chest X-ray. The ventricular ejection fraction was assessed by bedside echocardiography in the first 48 h after admission.
Data on dates of death were provided by the Slovenian National Cause of Death Registry. The study was approved by the local ethics committee.
End Points
The end point was all-cause long-term mortality in both groups.
Statistical Methods
We counted the end point events that occurred during the follow-up period and compared their rates between the cohorts of patients with and without AKI. The cumulative incidence rates of the unadjusted longterm mortality were estimated by the Kaplan-Meier method (stratified to AKI stages) and compared by the log-rank test.
We used binary logistic regression to identify independent predictors of AKI. Binary logistic regression models were performed using the Enter mode. The models were adjusted for variables that were significantly different in bivariate analysis: age, gender, diabetes, hyperlipidemia, ST-elevation myocardial infarction (STEMI), PCI of the left main coronary artery, PCI of the right coronary artery, intra-aortic balloon pump insertion, radial access, cardiogenic shock on admission, eGFR, contrast volume/eGFR ratio, TIMI flow after PCI, anemia, bleeding, bivalirudin, P2Y12 receptor antagonists, heart failure, and AKI. These variables were also used in Cox regression analyses. Cox proportional hazards regression was used to compute the hazard ratios (HRs) as estimates of long-term mortality according to the AKI stages. The proportional hazard assumption was evaluated by calculating the correlations between Schoenfeld residuals for each covariate and the ranked failure times. All correlations were close to zero and the p values were above 0.05, which implies that the assumption was met. The differences between the groups in baseline clinical, angiographic, and procedural characteristics were compared using the independent samples t test or the Mann-Whitney U test for continuous variables, and the χ 2 test for categorical variables, as appropriate. Data were analyzed with SPSS 21.0 software for Windows (IBM Corp., Armonk, NY, USA). All p values were two-sided and values less than 0.05 were considered statistically significant.
Results
Out of 5,859 MI patients, 499 (8.5%) suffered AKI. AKI stage 1 occurred in 362 (6.2%) patients, AKI stage 2 in 51 (0.9%) patients, and AKI stage 3 in 86 (1.5%) patients. Patients with AKI were generally older, female, admitted for STEMI, had diabetes, anemia, and renal dysfunction on admission, and presented more often with cardiogenic shock. On the contrary, 
Predictors of AKI
Cardiogenic shock, bleeding, age, heart failure, renal dysfunction, diabetes, hyperlipidemia, STEMI, and contrast volume/eGFR ratio predicted the development of AKI. Patients with radial access and those who received P2Y12 receptor antagonists suffered less AKI (Table 3) .
Mortality
Over a mean period of 4.2 ± 3.0 years, 1,389 (23.7%) patients died. Patients with AKI according to the KDIGO criteria had a higher mortality than patients without AKI (286 [57.3%] patients with AKI died compared to 1,103 [20. 6%] patients without AKI; p < 0.0001). Of the 362 patients with AKI stage 1, 182 (50.3%) died. In patients with AKI stage 2, 29 (56.9%), and in patients with AKI stage 3, 75 (87.2%) died, respectively. Figure 1a shows the unadjusted and Figure 1b the adjusted long-term mortality according to the AKI stages. The hazard ratio for all-cause mortality for AKI patients was 2.09 (95% CI: 1.80-2.43; p < 0.0001). The hazard ratio for AKI stage 1 patients was 1.77 (95% CI: 1.49-2.11; p < 0.0001), 1.85 (95% CI: 1.21-2.83; p = 0.005) for AKI stage 2, and 6.30 (95% CI: 4.68-8.48; p < 0.0001) for AKI stage 3 compared to patients with no AKI. Other predictors of long-term mortality are listed in Table 4 .
Discussion
Data on the long-term association of AKI according to the KDIGO guidelines in patients with MI are limited [5] . In our long-term follow-up study, we validated the KDIGO AKI criteria in unselected patients with MI treated with PCI. We followed patients for up to 10 years, with a mean of 4.2 years. We found that 8.5% of patients suffered AKI according to the KDIGO definition and that they had a 2.09 times greater long-term risk of dying than patients without AKI, which is consistent with previous reports [2, 15] . The main finding is that even AKI stage 1 almost doubled the long-term risk. A graded increase in the severity of AKI according to the KDIGO definition is associated with a progressively increased risk of long-term mortality in these patients. The prevalence of AKI was lower than in similar trials, probably because less contrast was used and good hydration was maintained in our study to prevent AKI [16] . Unfortunately, comparison is difficult due to the different study populations and different definitions of AKI and comparisons must be made in light of these differences. Beside patient characteristics, procedural data and outcome characteristics were included in the multivariable regression model to elucidate the risk factors predicting AKI. As previously found, cardiogenic shock on admission, diabetes, hypertension, renal dysfunction, STEMI, heart failure [2, 5, 15, 17, 18] , and contrast volume/eGFR ratio predicted AKI [5, 19] . In fact, this ratio seems to have a greater potential to discriminate between the patients who are at higher risk of AKI than the contrast volume alone since it includes 2 parameters (contrast volume and eGFR) that both predispose to AKI [19, 20] . The contrast volume/eGFR ratio also predicted long-term mortality. Besides sex and bivalirudin, for which the data are inconsistent, all other predictors of long-term mortality in our study (listed in Table 4 ) are well established [8, 9] . Bleeding after PCI more frequently complicated hospitalization in patients with AKI (unadjusted OR: 8.95; 95% CI: 7.06-11.09; p < 0.0001) and also predicted AKI, as previously seen [16, 18, 21, 22] .
Patients who did not receive P2Y12 receptor antagonists suffered more AKI. P2Y12 receptor antagonists were also an independent predictor of AKI. Some experimental animal data show that P2Y12 inhibition prevents glomerular injury and protects both glomerular and peritubular capillaries, but data on P2Y12 inhibition and AKI in patients are lacking [23] . Moreover, patients who did not receive P2Y12 receptor antagonists were sicker (older, with more STEMI, a higher prevalence of cardiogenic shock, diabetes, renal dysfunction and anemia, more IABP were implanted, they bled more, received more IIb/IIIa receptor antago- nists, they had less radial access, lower TIMI flow after PCI, and higher contrast/eGFR ratios). The role of P2Y12 receptor antagonists in AKI is strongly confounded by the clinical characteristics and still needs to be determined. Radial access was shown to be protective for AKI, which is consistent with previous reports [16] .
The result of our study may be relevant for the treatment of patients with MI in everyday practice. A slight increase in serum creatinine (> 0.3 mg/dL) almost doubles the long-term mortality risk in these patients. Therefore, we must obtain the serum creatinine value at hospital admission. We can easily define the patients who are prone to develop AKI (eGFR < 60 mL/min/1.73 m 2 , hemodynamic impairment, STEMI, diabetes, hypertension, hyperlipidemia, elderly) [1, [3] [4] [5] and instigate early nephroprotective strategies (low contrast volume, crystalloid infusions, measures to ensure optimal hemodynamics, discontinuation of nephrotoxic drugs, adjustment of anti-thrombotic drugs, radial access), which might provide a significant long-term benefit [5, 7, 16, 24, 25] . In cases of AKI, the consultation with a nephrologist would be beneficial for these patients.
Limitations
We did not follow the data on possible normalization of serum creatinine. This was an observational single-center study. Our data encompassed all-cause mortality only. Data on complications of PCI were not available for a sufficient number of patients to be considered in the evaluation. Data on medication (ACE inhibitors, ARB, statins), hyperuricemia, and glucose were not collected. Calculations of eGFR were based on creatinine at presentation, which may not have been in a steady state, and thus may not be a true estimate of patients' baseline kidney function. For the calculations of eGFR, we used the MDRD equation, whose accuracy and reliability decreases with extreme eGFR values.
Conclusion
Even a slight increase in serum creatinine (> 0.3 mg/dL) is important in MI patients undergoing PCI. A graded increase in the severity of AKI according to the KDIGO definition is associated with a progressively increased risk of long-term mortality in these patients.
